Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged royalty
Why did Acuitas bring a patent lawsuit against Arbutus?

The LNP patent battle lines are being drawn. In the past several weeks, Arbutus has sued Moderna, Alnylam has suedboth Moderna and Pfizer, and in the latest, Acuitas Therapeutics has sued Arbutus and Genevant. What can we expect from the Acuitas lawsuit?

Read More
Markman AdvisorsArbutus, Arbutus Biopharma, Genevant, Roivant, Moderna, Pfizer, BioNTech, LNP, lipid, lipid nanoparticle, cationic lipid, lawsuit, patent, license, IPR, royalty, Acuitas, Acuitas Therapeutics, Alnylam, Zachary Silbersher, Silbersher, ABUS, MRNA, PFE Comment
Is Novartis’ S1P modulator titration patent a “roadblock” to Celgene’s ozanimod?

While Bristol Myers ($BMY) proposed acquisition of Celgene’s ($CELG) remains in question by activists questioning Revlimid®’s pending patent cliff, a new patent angle emerges.  A Credit Suisse analyst recently identified a patent owned by Novartis ($NVS) that could purportedly act as a “roadblock” to Celgene’s MS drug ozanimod.  Is this true?

Read More
Markman AdvisorsCelgene, CELG, Novartis, NVS, Bristol-Meyers Squibb, BMS, BMY, Gilenya, multiple sclerosis, fingolimod, sphingosine-1-phosphate, S1P, titrate, titration, roadblock, Credit Suisse, ozanimod, prior art, Patent Office, injunction, royalty, reasonable royalty, Zachary Silbersher, SilbersherComment
What is the Dupixent® patent fight among Amgen, Regeneron and Sanofi all about?

Dupixent® is a recently-released drug forecasted to reach $4B in annual sales.  The drug is a co-venture between Regeneron and Sanofi, which also teamed up to launch Praluent®, one of the two available drugs within the new class of PCSK9-inhibitors.  In the case of Praluent®, Amgen brought Regeneron to court arguing that Praluent® infringed Amgen’s patents and thus the drug should be taken off the market.  Once again, Amgen, Regeneron and Sanofi are back in court.  Amgen has squared off against Regeneron and Sanofi and argued that Dupixent® infringes one of Amgen’s patents.

Read More
Markman AdvisorsAmgen, Regeneron, Sanofi, IPR, inter partes review, Praluent, PCSK9, IL-4, IL-13, IL-4R, Dupixent, dupilumab, patent, antibody, royalty, functional claim